Drug intelligence / Profile preview

atezolizumab + tesetaxel

Development stage: Preclinical
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination of atezolizumab, a PD-L1 inhibitor immunotherapy, and tesetaxel, a taxane chemotherapy agent. Atezolizumab works by blocking the PD-L1 protein that prevents the immune system from attacking cancer cells, while tesetaxel is a chemotherapy drug that likely works by preventing cancer cell division.

Brand names: Tecentriq

Targets

TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on atezolizumab + tesetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + tesetaxel.

Explore the full profile